Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
On August 10, 2017, Interpace Diagnostics Group, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2017. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Press Release dated August 10, 2017 (furnished to Item 2.02). |
|
Exhibit Number |
Description | |
| 99.1 | Press Release dated August 10, 2017. |
Interpace Diagnostics Group, Inc. ExhibitEX-99.1 2 ex99-1.htm Interpace Diagnostics Group Reports Second Quarter 2017 Financial Results,…To view the full exhibit click here
About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.